We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Psychological Management by Meditation of Full COnscience in Virtual REality of People With Amyotrophic Lateral Sclerosis: Effects on Cognition, Behavior, Quality of Life and Psychological Well-being (COREVALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05409508
Recruitment Status : Not yet recruiting
First Posted : June 8, 2022
Last Update Posted : June 15, 2022
Information provided by (Responsible Party):
University Hospital, Angers

Brief Summary:
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results in progressive paralysis of the muscles involved in voluntary motor skills, speech, swallowing and breathing. It also causes non-motor symptoms including psychological, cognitive and behavioral difficulties that have a negative impact on patients' quality of life, well-being and long-term development. There is no curative therapy for ALS and drug treatments have little effect on non-motor symptoms. Interventions based on mindfulness meditation, defined as a state of consciousness that arises when one decides to focus attention in the present moment without judgment on the real experience, seem to be a promising tool for the reduction of non-motor symptoms in a number of progressive neurological conditions (Alzheimer's disease, multiple sclerosis, etc.), suggesting that mindfulness significantly helps in the management of these symptoms. Our project therefore aims to implement a mindfulness meditation program adapted to the management of non-motor symptoms in ALS based on virtual reality (VR).

Condition or disease Intervention/treatment Phase
Lateral Sclerosis Amyotrophy Mindfulness Meditation Other: mindfulness meditation care Other: no mindfulness meditation care Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Psychological Management by Meditation of Full COnscience in Virtual REality of People With Amyotrophic Lateral Sclerosis: Effects on Cognition, Behavior, Quality of Life and Psychological Well-being
Estimated Study Start Date : September 2022
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : June 2023

Arm Intervention/treatment
Experimental: Patients with mindfulness meditation care Other: mindfulness meditation care
mindfulness meditation care

Active Comparator: Patients without mindfulness meditation care Other: no mindfulness meditation care
no mindfulness meditation care

Primary Outcome Measures :
  1. To assess the benefits of psychological care with mindfulness meditation in virtual reality versus psychological management without mindfulness meditation in virtual reality in terms of evolution over time [ Time Frame: at 3 months ]
    from a quality of life scale : ALSSQOL-R : the lower the score, the more the person feels a sense of well-being

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Majors to inclusion
  • Mother tongue: French
  • Patients for whom ALS of bulbar or spinal form defined according to El Escorial criteria is possible, probable or certain
  • Able to carry out the investigations and interventions provided for in the protocol
  • Signature of informed consent to participate in the study

Exclusion Criteria:

  • Participation in intervention research modifying management
  • History likely to disrupt cognition (constituted stroke, sequelae of traumatic brain injury, active epilepsy, learning disabilities, alcohol dependence syndrome, drug use, psychiatric disorders), severe cognitive impairment (MMSE <24)
  • People who meet the diagnostic criteria for Frontotemporal Dementia
  • Pregnant or lactating women
  • Persons deprived of their liberty by administrative or judicial decision
  • Persons undergoing psychiatric care under duress
  • Persons subject to a legal protection measure
  • Persons unable to express their consent
  • Persons not affiliated or not beneficiaries of a social security scheme
Layout table for additonal information
Responsible Party: University Hospital, Angers
ClinicalTrials.gov Identifier: NCT05409508    
Other Study ID Numbers: 2022-A01230-43
First Posted: June 8, 2022    Key Record Dates
Last Update Posted: June 15, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases